Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dorgenmeltucel-L (HyperAcute Melanoma) in Refractory or Recurrent Malignant Melanoma
NCT00300612Phase 2Completed
- Sponsor
- Lumos Pharma, Inc.
- Start
- Mar 2006
- Primary completion
- Sep 2007
- Modality
- Cell Therapies, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dorgenmeltucel-L in Malignant Melanoma (MM), sponsored by Lumos Pharma, Inc. Primary endpoints: Dose-Limiting Toxicity at 6 months and Maximum Tolerated Dose at 6 months. Started Mar 2006; status: completed.
02
Drugs
dorgenmeltucel-L
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00300612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00300612.